Search

Your search keyword '"Jacques, Cadranel"' showing total 753 results

Search Constraints

Start Over You searched for: Author "Jacques, Cadranel" Remove constraint Author: "Jacques, Cadranel"
753 results on '"Jacques, Cadranel"'

Search Results

101. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

102. Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

103. 1341P NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes

104. No evidence for a pathogen associated with pulmonary MALT lymphoma: a metagenomics investigation

105. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

106. Low income and outcome in idiopathic pulmonary fibrosis: An association to uncover

107. Targeted adjuvant therapy in non-small cell lung cancer : trick or treat?

108. Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay

109. Toxicités sévères immuno-induites par les inhibiteurs de points de contrôle immunitaire : implications pour le réanimateur

110. No Evidence for a Pathogen Associated With Pulmonary MALT Lymphoma: A Metagenomics Investigation

111. Pyogenic Lung Abscess in an Infectious Disease Unit, a 20-year Retrospective Study

112. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

113. Randomised trial of first-line bronchial artery embolisation for non-severe haemoptysis of mild abundance

114. Invited editorial: Q and A on hereditary lung cancer

115. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population.

116. Association between influenza vaccination and the occurrence of acute exacerbation inidiopathic pulmonary fibrosis

117. Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial

118. First-Line Afatinib plus Cetuximab for

119. Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies-a narrative review

120. The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey. International survey and call for consensus

121. Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19

122. An expert statment on clinical considerations before treating NTM lung infection

123. Gender differences in idiopathic pulmonary fibrosis: are men and women equal or not?

124. Low income and progression free survival in idiopathic pulmonary fibrosis: an association to uncover

125. Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival

126. Prevalence of tobacco and cannabis use in a prospective cohort of spontaneous pneumothorax and cessation rate at 6 months

127. Lorlatinib for advanced ALK and ROS1+non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort

128. The DIAMORFOSIS (Diagnosis and Management of Lung Cancer and Fibrosis) Survey

129. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series

130. Detection of secondary causes of spontaneous pneumothorax: Comparison between computed tomography and chest X-ray

131. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents

132. Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study

133. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project

134. Mise au point sur la maladie des anticorps anti-membrane basale glomérulaire ou syndrome de Goodpasture

135. Integrative Medicine in Interventional Oncology: A Virtuous Alliance

136. Current challenges in the management of nonsmall cell lung cancer brain metastases

137. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial

138. Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm

140. Professional exposure to goats increases the risk of pneumonic-type lung adenocarcinoma: results of the IFCT-0504-Epidemio study.

141. Les principes de l’analyse médico-économique appliqués au cancer du poumon

142. Classification histomoléculaire des cancers pulmonaires

143. Évaluation, prévention et gestion des toxicités de la chimiothérapie, des anti-angiogéniques et de l’immunothérapie

144. Le sevrage tabagique : éviter le cancer, réduire la toxicité des traitements et le risque de rechute

145. Le patient douloureux

146. Impact de l’amélioration de la filière diagnostique sur le pronostic

147. Effect of cannabis and tobacco on emphysema in patients with spontaneous pneumothorax

148. New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey

149. Hémorragies intra-alvéolaires

150. Hémorragies intra-alvéolaires auto-immune en rhumatologie

Catalog

Books, media, physical & digital resources